Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer
Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.
Read the full story at NPR Health ↗
ImpactNotable 49/100
Why it mattersnimble: medium (p 0.62)
RegionsUnited States
Published1 d ago (Mon, 26 Oct 2026 08:42:43 GMT)
RetrievedMon, 26 Oct 2026 09:00:33 GMT via rss
ClassifiedMon, 26 Oct 2026 09:01:57 GMT by nimble
AuthorYuki Noguchi